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Abstract. Nicotine, the major psychoactive com-
pound in tobacco, acts as a potent addictive drug in
humans. The addictive nature of nicotine leads to
more than 6 million deaths a year. Evidence indicates
that nicotine and other drugs of abuse act on central
dopaminergic pathways and modulate their neurophysi-
ological mechanisms. Nicotine stimulates dopaminergic
pathways and the prefrontal cortex (PFC), inducing en-
hanced reward perception and increased cognitive func-
tion, respectively. These findings are consistent with the
fact that nicotine binds to different subtypes of nicotinic
acetylcholine receptors present on the neurons found in
the PFC and ventral tegmental area of the midbrain.
The latter, being the area most involved in addictive be-
haviour, projects to the limbic system, particularly the
nucleus accumbens, and receives afferents from the pre-
frontal cortex and brainstem. Although dopaminergic
pathways and nicotinic acetylcholine receptors are the
protagonists of nicotine addiction, several minor path-
ways and their constituent receptors have been indicated
as being either directly or indirectly affected by nico-
tine. These include serotonergic pathways and central
cannabinoid receptors. Despite the scarcity of approved
drugs and partial efficacy of approved treatment, insight
into nicotine neurophysiological modulation has led to
a better appreciation of nicotine-seeking behaviour and
subsequent improved design of pharmacological and be-
havioural approaches to smoking cessation. Tobacco
is the single most preventable cause of death in the
world today. Better understanding of the neurobiologi-
cal mechanisms underlying nicotine addiction will ulti-
mately lead to more effective treatments of both nicotine
dependence and nicotine rewarding effects.
Keywords Nicotine – Addiction – Withdrawal – Nico-
tinic acetylcholine receptors – Corticolimbic pathways –
Smoking cessation.
1 Introduction
Tobacco is the single most preventable cause of death
in the world today. The World Health Organisation
(WHO) estimates that annually, tobacco leads to more
than 6 million deaths and causes more than half a trillion
American dollars of economic damage (World Health
Organisation, 2013). Many types of tobacco products
are consumed all over the world but the most popu-
lar form of nicotine use is through cigarette smoking.
Smoking is a ubiquitous activity: more than 5,550 bil-
lion cigarettes are manufactured annually and there are
approximately 1.2 billion smokers worldwide– a number
expected to increase to 2 billion by 2030 (Mackay and
Eriksen, 2012; World Bank, 2003). Tobacco use and its
health hazards are therefore a global burden and show
how tobacco is a strong motivator, despite the increased
awareness of its consequential health hazards. This re-
view will summarise knowledge of the neurophysiology
of the addictive behaviour elicited by nicotine, the major
psychoactive agent present in all tobacco products.
2 Addiction – Theories and Neu-
robiology
Addiction is a complex phenomenon which is still not
completely understood. The traditional view is that ad-
dictive substances, such as ethanol, psychostimulants,
opioids and nicotine, are all taken for two reasons: ei-
ther for the pleasure the drugs elicit or to avoid the
unpleasant consequences of withdrawal (World Health
Organisation, 2004). Addiction is not the mere use of
those drugs - it is the inability to ceasing drug intake and
a compulsive pattern of drug-seeking and drug-taking
behaviour that takes place at the expense of other ac-
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tivities (Robinson and Berridge, 2000). Moreover, the
non-addictive, sporadic or occasional patterns of intake
of an addictive drug might escalate to a frequent and
compulsive one (Wellmann et al., 2004).
3 Manifestations of Addiction
The transition from sporadic, intermittent use to com-
pulsive intake is a result of the interaction of the addic-
tive substance with central neurones. This leads to long-
lasting neuronal alterations of metabolism and activity,
and consequently, the properties of the neuronal circuits
that they constitute (Mansvelder and McGehee, 2002).
This progressive change in neuronal circuitry leads to
a manifestation of complex behaviours such as depen-
dence, tolerance, sensitisation and craving (Kobb and
Le Moal, 2008).
As defined in the 2010 version, 10th revision of the In-
ternational Classification of Disease (ICD-10) classifica-
tion of mental and behavioural disorders (WHO, 2010),
substance use dependence is diagnosed whenever a case
is positive on at least three of six criteria (appendix 1).
Tolerance and withdrawal are two of them. Tolerance is
defined as the idea that increased amounts of drug are
required to achieve the same hedonic effect, or, that the
same amount produces less effect. Withdrawal is the oc-
currence of unpleasant physical and physiological symp-
toms when use of the substance is reduced or discontin-
ued (WHO, 2010). During discontinuation, relapse to
substance use is known to be triggered by cues previ-
ously paired with substance use, by stress, or by pres-
ence of the drug itself (Stewart, 2000). This is elicited
by uncontrollable desire for drugs, craving – a concept
to which there is still no definite definition, due to a lack
of applicability of biological models to it (Drummond et
al., 2000).
In the 5th revision of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-V) (American Psy-
chiatric Association, 2013), unlike all previous versions,
the criteria for substance abuse and substance depen-
dence have been combined into one category, termed ad-
dictions and related disorders, and specifically expanded
for each substance of abuse. Each substance use disorder
is then divided into mild, moderate and severe subtypes.
Moreover, whereas the DSM-IV substance abuse diag-
nostic criteria was requiring only 1 symptom, a DSM-V
diagnosis now requires at least 2 (American Psychiatric
Association, 2013).
4 Theories of Addiction
The mere intake of such chemicals is not equivalent to
addiction. In fact, it is the properties of the chemical,
together with the individual’s genomic and behavioural
background, which predispose an individual to addic-
tion (Nees et al., 2013; Kendler et al., 2000). Indeed,
this multifaceted phenomenon also leads to a variety of
theories as to how addiction evolves.
As stated earlier, the traditional view, and the mostly
intuitive explanation of addiction, is that addictive sub-
stances are taken as a result of either positive or neg-
ative reinforcement (Koob and Le Moal, 2008; World
Health Organisation, 2004). Both these views have their
shortcomings since it is not always the case that drugs
produce such effects. For example, psychostimulants
do not produce strong withdrawal syndromes, but can
be highly addictive. On the contrary, anticholinergics,
κ-opioid agonists and tricyclic antidepressants produce
tolerance and withdrawal syndromes, but do not sup-
port compulsive patterns of use (Cote et al., 2013). Also,
as stated by the pioneer of the reinforcement model
(Skinner, 1953), that a stimulus reinforces a particu-
lar type of behaviour is merely an observation, and not
an explanation of how the former leads to the latter.
A more holistic theory is the incentive-sensitisation
theory of addiction (Robinson and Berridge, 1993). The
theory states that all addictive drugs share the ability
to produce long-lasting sensitisation of neural systems
that subserve a subcomponent of reward – incentive
salience. Drug-sensitised incentive salience causes drugs
to become compulsively and enduringly wanted (which
is different from liking), independent of drug pleasure,
withdrawal, habits or memories. This phenomenon is
implicit, as it can guide behaviour without a person nec-
essarily having conscious emotion, desire, or a declara-
tive goal (Robinson and Berridge, 2003, 2000, 1993).
Robinson and Berridge (1993) also make it clear that
in some cases and individuals, the positive and negative
reinforcement models of addiction do apply.
5 Neuroanatomy of Addiction
All psychoactive drugs modulate the normal physiology
of the central dopaminergic (DAergic) system (Wise,
1998) via different mechanisms. Therefore, an insight
into the central DAergic pathways, particularly the nu-
cleus accumbens-related circuitry, is paramount for the
understanding of addiction.
Central dopamine (DA) is found mainly in neurons
located in the ventral midbrain, especially the substan-
tia nigra pars compacta (SNc) and the nearby ventral
tegmental area (VTA). Three projection systems have
been described arising from these mesencephalic nu-
clei: the mesostriatal (nigrostriatal), mesocortical and
mesolimbic pathways (Blumenfeld, 2010). The mesos-
triatal pathway arises from the SNc and projects to the
dorsal striatum: the caudate and the putamen. The
mesocortical pathway arises mainly from the VTA and
projects to the prefrontal cortex (Crossman and Neary,
2010). The roles of the mesocortical projections are to
increase working memory and attention span, and the
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roles for the mesostriatal pathway are to modulate in-
tentional aspects and magnitude of locomotor activa-
tion (Blumenfeld, 2010). These pathways are affected
by nicotine, but merely contribute in the reinforcement
effect that it has on the human nervous system.
Finally, the mesolimbic pathway arises from the VTA
and projects primarily to the nucleus accumbens (NAcc)
of the ventral striatum – an area of the limbic sys-
tem (Blumenfeld, 2010). Most addictive drugs, includ-
ing nicotine, increase DA levels in the NAcc (Cote et
al., 2013; Khalki et al., 2013; Nees et al., 2013). Ev-
idence shows that VTA lesions and DA receptor an-
tagonist microperfusion in the NAcc results in reduced
self-administration of many addictive drugs, including
nicotine (Mansvelder and McGehee, 2002). Obviously,
the NAcc-related circuitry did not evolve to mediate the
effects of drugs; its evolutionary intent is to use stimuli
beneficial for survival, such as nutrients, water and sex-
ual partners as natural rewards that exert motivational
control over behaviour (Kelley and Berridge, 2002).
Despite the established linkage of NAcc DA levels and
reward, several studies are now suggesting that this is
an indirect causal relationship, since it seems that DA in
the NAcc signals novelty or reward expectation, rather
than reward itself (Berke and Hymann, 2000; Dani and
De Biasi, 2001; DiChiara, 2000; Schultz et al., 1997).
Such research correlates with the incentive-sensitisation
theory of addiction (Robinson and Berridge, 1993).
6 The Addictive Nature of To-
bacco
Although tobacco contains substances (such as norni-
cotine and monoamine oxidase inhibitors) which con-
tribute to tobacco addiction, nicotine, an alkaloid, is
the main psychoactive agent (Khalki et al., 2013; Sasaki,
2013). The average human plasma half-life of nicotine
is approximately 2 hours, but is about 35% longer in in-
dividuals with a particular form of the gene coding for
the cytochrome P450 CYP2A6 that is responsible for
the primary nicotine metabolic pathway (Ande et al.,
2012).
Nicotine acts as an agonist at several populations of
both central and peripheral nicotinic acetylcholine re-
ceptors (this review tackles central receptors only). In
humans, acute nicotine administration produces pos-
itive effects, including mild euphoria and mildly en-
hanced cognition; such subjective positive effects sup-
port intravenous self-administration behaviour in a vari-
ety of mammalian species including mice, rats and non-
human primates (Markou and Peterson, 2001; Picciotto
and Corrigall, 2002). Persistent nicotine use leads to tol-
erance that is mediated by neuroadaptation occurring
in response to chronic exposure to the alkaloid, thus,
within hours upon cessation of nicotine exposure, a nico-
tine withdrawal syndrome emerges. This syndrome is
characterized by depressed mood, mild cognitive deficits
and irritability (Shiffman et al., 2004).
In both rats and humans, nicotine withdrawal is char-
acterized by both increases in somatic signs and effec-
tive changes such as reward deficits (Jonkman et al.,
2007). Jonkman and colleagues (2007) also suggest
that, despite no elicitation of an anxiogenic effect it-
self, nicotine withdrawal potentiates response to anx-
iogenic stimuli. On the same lines, intracranial self-
stimulation (ICSS) studies on rats (Harrison et al., 2002;
Johnson et al., 2008) showed that after being adminis-
tered nicotine, they required lower self-applied current
intensities to their reward centres to perceive pleasure.
On the other hand, after withdrawal from nicotine, rats
required higher intensities to perceive rewarding stim-
uli. Similarly, other studies showed that rats chronically
treated with nicotine required higher current intensities
when administered nicotinic receptor antagonists, such
as dihydro-β-erythroidine (DHβE) (Watkins et al., 2000)
or mecamylamine (MEC) (Hollander and Kenny, 2008).
The same antagonist studies also showed that control
rats (not treated with nicotine), had the same reward
threshold recorded under baseline conditions after be-
ing administered DHβE.
Moreover, learning processes also contribute to nico-
tine dependence. For example, environmental stimuli
associated with either the positive subjective effects of
nicotine or the induction of nicotine withdrawal moti-
vates nicotine seeking and eventually drug consump-
tion (Kedikian, Faillace and Bernabeu, 2013). Stud-
ies on rats (Kenny and Markou, 2006) have shown
this phenomenon by pairing flashing light with the ef-
fects of DHβE under classical conditioning processing.
Those studies showed significant elevations of the re-
ward thresholds once conditioned pairing was success-
ful. An increased threshold was not observed in rats
that had equal exposure to nicotine with unpaired light
and DHβE. Such studies therefore indicate that nicotine
withdrawal can be paired with environmental stimuli
which alone can precipitate withdrawal syndrome.
7 Central Nicotinic Acetyl-
choline Receptors
Nicotinic acetylcholine receptors (nAChRs) are ligand-
gated ion channels comprising five membrane-spanning
subunits (Changeux and Taly, 2008; Purves, 2011).
Binding of the agonist is transduced into the gating
of the receptor ion channel pore that is permeable to
multiple cationic species (Na+, K+, Ca2+) and large or-
ganic cations such as tetraethylammonium (TEA) (Fu-
cile, 2004). 12 genes encode neuronal nAChRs sub-
http://dx.medra.org/10.7423/XJENZA.2013.2.09 http://www.mcs.org.mt/
Nicotine Addiction: A Review 75
units: genes CHRNA 2 to 10 encode nine isoforms of
the neuronal α-subunit (α2- α10) and genes CHRNB 2
to 4 encode three isoforms of the neuronal β-subunit (β2
- β4) (Elgoyhen et al., 2001; Le Novere et al., 2002).
Subunits either combine with different stoichiometries,
such as two α- and three β-, or five α7-subunits to form
nAChRs with distinct pharmacologic and kinetic prop-
erties (Mansvelder and McGehee, 2002).
Such distinct properties include abundancy, Ca2+ per-
meability, and sensitivity to nicotine and desensitisation
rates (Wonnacott et al., 2005). The heteromeric α4β2
nAChR (α4β2*) forms the majority of central nAChRs
while the homomeric α7 nAChR (α7*) is the second
biggest in number (Millar and Gotti, 2009). α7* are
mostly permeable to Ca2+, having fractional Ca2+ cur-
rents of 6-12% (Fucile, 2004), comparable to Ca2+ cur-
rents recorded in N-methyl-D-aspartate (NMDA) recep-
tors and considerably greater than that of heteromeric
(α4β2) nAChRs (2-5%) (Haghighi and Cooper, 2000). It
follows, as will be later elaborated, that both types lead
to increased Ca2+ permeation: directly via α7* and in-
directly by the activation of voltage-dependent calcium
channels (VDCCs) through α4β2*-mediated depolarisa-
tion (Beker et al., 2003; Dajas-Bailador et al, 2002).
α4β2* have the highest affinity to nicotine since they
are activated even with nicotine concentrations as low
as 100-500nM (Dani et al., 2000; Millar and Gotti,
2009). Such high affinity leads to rapid desensitisation
once a compatible ligand (such as ACh and nicotine)
binds to this subtype (Mansvelder et al., 2002a). On
the other hand, α7* are renowned for their multi-gating
modes (Papke et al., 2000). α7* manifest relatively
rapid desensitisation at relatively high ACh concentra-
tions (100μM or higher) (Papke, 2006). On the other
hand, α7* undergo non-desensitising activation at low
ACh concentrations of 20μM (Gourlay and Benowitz,
1997; Mansvelder et al., 2002). Such phenomenon sug-
gests that since such concentrations are present in in
vivo cerebrospinal fluid (CSF), it is possible that there
is a tonic activation of α7* under normal physiological
conditions. Such tonicity ceases at high concentrations
due to inactivation and desensitisation (Papke, 2006).
8 Central Location
Numerous studies show that nicotine stimulates the re-
lease of numerous neurotransmitters since nAChRs are
situated in different areas of the DAergic pathways and
their modulatory circuits. This section will expand on
how the expression of the two main subtypes of nAChRs
in the corticolimbic structures, mainly the VTA and
PFC, lead to the behaviour that nicotine addiction ex-
hibits. Modulation of mesencephalic and PFC output
is ultimately due to the balance of excitatory and in-
hibitory inputs and the intrinsic activity of the neuronal
circuits.
Figure 1: Simplified schematic of the main inputs and outputs of
the ventral tegmental area, related nicotinic acetylcholine recep-
tors and neurotransmitters.
The main excitatory inputs to the VTA DAergic neurons are glu-
tamatergic projections that mainly come from layer 5 of the pre-
frontal cortex (PFC). Conversely, the principal inhibitory inputs
to the VTA are γ-aminobutryric acid (GABA)-secreting neurons
which are both local (VTA) interneurons and projections from
the NAcc and the ventral pallidum. Cholinergic projections to
the VTA come from two brainstem nuclei: the pedunculopontine
tegmental nucleus (PPTg) and the lateral dorsal tegmental nu-
cleus (LDTg).
Non-α7 nicotinic acetylcholine receptors (nAChRs) can excite
dopamine (DA) and γ-aminobutryric acid (GABA) neurons di-
rectly, while α7 nAChRs can enhance release from glutamatergic
terminals. Endogenous acetylcholine (ACh) release from brain-
stem cholinergic neurons contributes to the GABAergic input to
VTA DA neurons.
In the presence of nicotine concentrations similar to those found
in a smoker’s blood, the non-α7 nicotinic acetylcholine receptors
(nAChRs) desensitise rapidly, effectively inhibiting GABAergic
inputs to the dopamine (DA) neurons. The α7 nAChRs will not
desensitise as much, which means that glutamatergic inputs will
be enhanced as the GABAergic inputs are depressed, thus leading
to a net increase in excitation of the DA neurons.
PFC prefrontal cortex, NAcc nucleus accumbens, GP globus
pallidus, VTA ventral tegmental area, PPTg pedunculopontine
tegmental nucleus, LDTg lateral dorsal tegmental nucleus Glu glu-
tamate, GABA γ-aminobutryric acid, DA dopamine, ACh acetyl-
choline, nAChR nicotinic acetylcholine receptor.
9 Ventral Tegmental Area
As shown in Fig.(1), the main excitatory inputs to
the VTA DAergic neurons are glutamatergic projections
that mainly come from layer 5 of the prefrontal cortex
(PFC-V) (Couey et al., 2007). Conversely, the princi-
pal inhibitory inputs to the VTA are γ-aminobutryric
acid (GABA)-secreting neurons which are both local
(VTA) interneurons and projections from the NAcc
(medium spiny neurons) and the globus pallidus (GP)
(Mansvelder et al., 2002b). Cholinergic projections to
the VTA come from two brainstem nuclei: the peduncu-
lopontine tegmental nucleus (PPTg) and the lateral dor-
sal tegmental nucleus (LDTg) (Mansvelder and McGe-
hee, 2002b).
There are three neuronal components in the VTA that
express nAChRs: DA neurons, GABA neurons and glu-
tamatergic presynaptic terminals that synapse on the
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DA neurons (Fig.(1)) (Mansvelder and McGehee, 2002).
DA neurons express messenger ribonucleic acid (mRNA)
for many different nAChR subunits which give rise to at
least 3 types of nAChRs, with α4β2* and α7* being the
majority (Klink et al., 2001; Pidoplichko et al., 2004).
GABA neurons in the VTA express nAChRs that con-
tain α4 and β2 subunits (Mansvelder et al., 2002b) - this
has been shown since GABA neurons in the VTA have
been blocked by MEC at concentrations that specifi-
cally block non-α7*. Moreover, MEC microinfusion in
the NAcc did not lead to a decrease in DA, thus showing
that NAcc medium spiny neurons themselves express lit-
tle, if any, nAChRs.
Similar VTA microinfusion studies (Shilstrom et al.,
1998), this time with the NMDA receptor antagonist
(2R)-amino-5-phosphonovaleric acid (APV), inhibited
nicotine-induced increase of DA in the NAcc. This
therefore suggests that nicotine modulates glutamate
vesicle release at presynaptic glutamatergic terminals.
Along the same lines, another study (Mansvelder and
McGehee, 2000) showed three phenomena: 1) low-
concentration nicotine infusions enhanced VTA gluta-
matergic transmission (showing the role of nicotine in
glutamatergic release), 2) tetrodoxin (TTX), a Na+
voltage-gated channel blocker, did not affect this en-
hancement (showing a Na+-dependent neurotransmit-
ter release), and that 3) nAChRs are sensitive to
metyhyllycaconitine (MLA), a selective α7* antagonist
(showing that the Ca2+-permeant α7* are involved).
Furthermore, Jones and Wonnacott (2004) concluded
that α7* are situated on vesicular glutamate transporter
(vGluT) positive terminals that were devoid of vesicu-
lar cholinesterase transporter (VChat) staining. Such
events therefore suggest the presence of only, or a vast
majority of, α7 nAChRs on glutamatergic, not cholin-
ergic terminals of VTA DAergic neurons (Couey et al.,
2007). In conclusion, secondary to this configuration,
glutamatergic projections onto the VTA exert the great-
est effect of nAChRs agonists onto VTA DA neurons via
axodendritic influences.
10 Prefrontal Cortex
The PFC receives glutamatergic inputs from the me-
dial dorsal nucleus of the thalamus (Tmd) (Blumenfeld,
2010). Nicotine excites these thalamocortical projec-
tions, leading to an increase in glutamatergic inputs to
layer 5 pyramidal neurons as well as to some in layer
6 (Couey et al., 2007). Such effects were blocked by
TTX and were elicited with low concentrations of nico-
tine – both phenomena that indicate the presence of
α4β2 nAChRs (Lambe et al., 2003). The same authors
also demonstrated that nicotinic modulation of thalam-
ocortical inputs was absent in β2-containing nAChRs
knockout (KO) mice. More recently though, studies
showed that both α7 and non-α7 nAChRs appear to
be important in the PFC synaptosomes (Wallace and
Bertrand, 2013). This occurrence is similar to that in
the VTA with regards to Ca2+ permeation, although
different mechanisms are responsible for such ion flux.
PFC α7* are primarily found on ryanodine positive ter-
minals and their activation leads to calcium-induced cal-
cium release (CICR). On the other hand, as in the VTA,
activation of non- α7* increases Ca2+ via recruitment of
VDCCs (Mansvelder et al., 2009).
Although no studies have yet pinpointed the spe-
cific location of the different nAChRs subtypes, it can
still be ascertained that no nAChRs are present on the
pyramidal neurons (Couey, 2007). In contrast, specific
GABAergic interneuron populations do express mRNA
for α4, β2 and α7 subunits; the regular-spiking non-
pyramidal (RSNP) interneurons and the low-threshold-
spiking (LTS) interneurons (Couey, 2007). nAChRs are
also expressed on the medial dorsal thalamic projection
terminals (Mansvelder et al., 2009). PFC-V neurons
project to various sites, including the ventral striatum
(25% circa), hypothalamus (25% circa), amygdala (8%)
and the VTA (4%) (Gabbott, 2005).
11 Nicotine and Neurophysiolog-
ical Adaptations
During cigarette smoking, blood nicotine levels reach
300-500nM several minutes after the initiation of smok-
ing and concentrations close to 250nM are sustained for
10 minutes or more (Gourlay and Benowitz, 1997). Such
values disrupt the normal activity of central nAChRs
which lead to modulation of normal synaptic physiol-
ogy. Nicotine in the central nervous system activates the
high-affinity (α4β2) nAChRs which desensitize within
minutes (Dani et al., 2000). However, in vivo biochem-
ical studies showed that a single systemic injection of
nicotine enhances DA release in the NAcc for more than
an hour (Di Chiara, 2000). This conclusion indicates
that it is very likely such changes can be induced even
after a person smokes only one cigarette.
These findings lead to the assertion that nicotine
has long-lasting neurophysiological effects, which out-
last short-term nAChR stimulation and desensitisation
(Jiang and Role, 2008; Kawai et al, 2007). This up-
regulation has previously been reported to solely involve
an increase in the number of nAChR receptors (Wonna-
cott, 1990; Marks et al., 1992). Recent studies, although
not denying an increase in receptor number, suggest that
up-regulation is a change in receptor state, rather than a
change in receptor number (Mansvelder and McGehee,
2002). Such nicotine-induced up-regulation, by which
these long-lasting stimulatory effects ensue, are long-
term potentiation (LTP) and depression (LTD) of exci-
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tatory glutamatergic inputs of GABAergic transmission
in both the PFC and VTA.
Figure 2: Simplified schematic of the main inputs and outputs of
the prefrontal cortex, related nicotinic acetylcholine receptors and
neurotransmitters
Nicotinic acetylcholine receptors (nAChRs) are expressed on glu-
tamatergic thalamocortical projections and somata of GABAer-
gic rapid-spiking non-pyramidal cells (RSNP) and low-threshold-
spiking interneurons (LTS). GABAergic fast-spiking interneurons
(FS) and pyramidal cells do not express nAChRs. Glutamater-
gic thalamocortical stimulation is increased by nicotine, eliciting
an increased excitatory drive to the pyramidal neurons, LTS and
FS components. RSNP cells are directly depolarised by nicotine.
The net effect is therefore increased inhibition of pyramidal cells
activity.
Tmd medial dorsal nucleus of thalamus, PFC prefrontal cortex,
nAChR nicotinic acetylcholine receptor, Glu glutamate, GABA
γ-aminobutryric acid, LTS low-threshold-spiking interneurons,
RSNP rapid-spiking non-pyramidal cells, FS fast-spiking in-
terneurons, nAChR nicotinic acetylcholine receptor.
12 Prefrontal Cortex Modula-
tion
In normal mouse PFC, nAChRs lead to LTP by pair-
ing the stimulation of the excitatory inputs to layer 5
pyramidal neurons with postsynaptic spikes elicited 5ms
after each synaptic response (Couey, 2007). Such synap-
tic plasticity is brought about by the relative timing of
APs in presynaptic and postsynaptic spikes and is hence
referred to as spike-timing-dependent plasticity (STDP)
(Mansvelder et al., 2009). In STDP, a presynaptic spike
preceding a postsynaptic one by a short time window
leads to LTP; the reverse order leads to LTD. This co-
ordinated, LTP-inducing stimulus is disrupted following
nicotine infusion and a depression is subsequently ob-
served (Couey, 2007). Evidence shows that it is the
increase in GABAergic input from interneurons (RSNP,
fast-spiking (FS) and LTS) that brings about such de-
pression since the nicotinic modulation of PFC plas-
ticity was abolished by GABAA receptor antagonists
(Mansvelder et al., 2009). As shown in Fig.(2), increase
in GABAergic input is elicited by the nicotine-induced
increase in glutamatergic inputs from the thalamic pro-
jection terminals, which synapse on pyramidal neurons
and FS, both of which do not express nAChRs, and
on LTS. Moreover, nicotine directly depolarises RSNPs,
which do not have connections with thalamic projec-
tions, and LTS. Thus, in the PFC the overall effect of
nicotine-induced nAChR activation results in a net in-
hibition of pyramidal cell activity.
Recalling the various PFC projections; such nicotine-
induced modulation has widespread effects which to
date are still controversial (Mansvelder et al., 2009). For
example, Day et al. (2007) report that the nicotine-
induced threshold for STDP could reduce cognitive per-
formance. Conversely, the same study suggests that nor-
mal PFC-based stimuli during cognitive behaviour in-
creases PFC neuronal activity and therefore makes LTP
possible again. Such nicotine-dependent phenomenon
could therefore enhance the signal-to-noise ratio (con-
sequently decreasing the unwanted perturbations which
all neuronal synapses manifest) and thus leading to im-
proved cognitive performance.
13 Ventral Tegmental Area Mod-
ulation
4% of the PFC projections in layer 5 extend to the VTA
(Gabbott, 2005). As already mentioned, nicotine is able
to increase the firing rate of DA neurons. This happens
both by direct nicotine stimulation on VTA DA neurons
and actions on nAChRs located on GABAergic interneu-
rons and glutamatergic terminals in the VTA (Fig.(1)).
Glutamatergic transmission onto DA neurons is en-
hanced by activation of presynaptic nAChRs α7*. Inter-
estingly, cholinergic terminals are not in close proxim-
ity to glutamatergic terminals and therefore, in normal
physiological conditions, ACh stimulates such terminals
via a volume mode (Jones and Wonnacott, 2004). This
volume mode stimulation is disrupted with nicotine and
an increase in glutamatergic secretion occurs. At the
same time, the various types of nAChRs on DA neurons
are stimulated by the alkaloid, resulting in favourable
conditions for the pre- and post-synaptic paired activa-
tion leading to LTP of glutamatergic inputs (Mansvelder
and McGehee, 2000). LTP is also induced in vivo by
an increased AMPA/NMDA receptor ratio (Saal et al.,
2003).
Recalling that α7* are tonically active at low neu-
rotransmitter (NT) concentrations, these receptors are
not significantly desensitised by low nicotine concen-
trations associated with tobacco smoking (Gourlay and
Benowitz, 1997; Mansvelder et al., 2002a). This en-
sures that nicotine-induced glutamatergic-DAergic LTP
remains unaltered.
In addition to glutamate and dopamine, GABA plays
another important role in VTA circuitry. GABAergic in-
terneurons, which predominantly express α4β2 nAChRs,
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undergo a transient increase of inhibitory input to the
DA neurons. This effect would likely give rise to a
short-lived offset of some of the excitatory effects of
nicotine, an event that subsides within minutes since
the high-affinity α4β2 nAChRs undergo rapid desensiti-
sation. Also, both physiologic (Fiorillo and Williams,
2000) and ultrastructural analyses (Garzo´n et al., 1999)
of VTA cholinergic transmission conclude that the vast
majority of brainstem cholinergic projections synapse
on GABAergic interneurons while very few synapse on
DAergic ones.
An important question is whether VTA GABAergic
depression actually contributes to nicotine addiction. In
fact, there is evidence (David et al., 1997; Ikemoto et al.,
1997) that rats and mice readily self-administer GABAA
receptor antagonists in the VTA. Acetylcholinesterase
inhibition also enhanced GABA transmission in the
VTA and DA in the NAcc (Mansvelder et al., 2002b)
- a phenomenon which complements the results of stud-
ies asserting that the majority of cholinergic projections
end on GABA interneurons. Such evidence therefore
suggests that, as shown in Fig.(2), GABAergic desen-
sitisation will also lead to the cessation of most of the
cholinergic effect on DAergic inhibition.
In summary, under normal physiological conditions
α4β2* can excite DA and GABA neurons directly, while
α7* enhance release from glutamatergic terminals and
the somata of DA neurons. Endogenous ACh release
from brainstem cholinergic neurons, apart from a scarce
effect on DAergic neurons and the far-off glutamatergic
terminals, mainly affects GABAergic input to VTA DA
neurons. In the presence of nicotine concentrations sim-
ilar to those found in the blood of a smoker, the α4β2*
on GABAergic interneurons desensitize rapidly leading
to the cessation of cholinergic influence on their somata
and DA neuron disinhibition. α7* do not desensitise
as much which means that glutamatergic inputs will be
enhanced. The net effect is therefore an increase in ex-
citation of the DA neurons via glutamatergic LTP and
GABAergic depression. GABAergic depression might
also help in further glutamatergic potentiation as it fur-
ther favours DAergic neuron depolarisation (Mansvelder
and McGehee, 2002). Such effects, which outlast nico-
tine exposure by hours or more, definitely contribute to
our understanding on the long-lasting addictive effects
of nicotine.
14 Others
Numerous other NTs and neuromodulators influence
the activity of the VTA, including serotonin (5-HT)
and endogenous opioids (Tzschentke, 2001). Seth et al.
(2002), although not able to pinpoint direct evidence for
presynaptic nAChRs on cortical serotonergic terminals,
showed that 5-HT levels increase on nicotine exposure.
Conversely, and more recently, studies conducted on rats
reported that nicotine decreased serotonergic cell activ-
ity in the dorsal raphe nucleus (dRN) (Touiki et al.,
2007).
There is also evidence in humans for a role of en-
dogenous opioids in mediating nicotine dependence
(Krishnan-Sarin et al., 1999). Anandamide, an endo-
cannaboid, is indeed implicated in nicotine addiction
since its levels in the forebrain and midbrain increase on
chronic nicotine administration (Merritt et al., 2008).
15 Pharmacological Treatment
for Nicotine Addiction
Although it is not the aim of this review to highlight
the pharmacological approach to treat nicotine addic-
tion, a brief outline of the current approaches and of
promising novel compounds undergoing preclinical test-
ing complement the above evidence of the mechanisms of
nicotine addiction, which ultimately has effective smok-
ing cessation as its main objective. The pharmacolog-
ical treatment of nicotine addiction is divided into two
approaches: substitution or eradication (Di Matteo et
al., 2007). In addition, pharmacological approaches are
more effective when administered during behavioural
counselling (Galanti, 2008; Hurt et al., 2009; World
Health Organisation, 2004). To date, varenicline is
the first-line pharmacotherapy, which demonstrates the
greatest efficacy when combined with behavioural sup-
port (Carson et al., 2013; West et al., 2008).
16 Nicotine Replacement Treat-
ment
Substitutive treatment involves giving nicotine in vari-
ous formulations in order to substitute tobacco nicotine,
hence the term nicotine replacement therapy (NRT)
(Hurt et al., 2009). Such treatment is effective since
most adverse health effects of tobacco smoking come
not from the nicotine itself, but from tars and carbon
monoxide, released when tobacco products are ignited
(World Health Organisation, 2004). For example, a
nicotine transdermal patch provides a relatively stable,
fixed dose of nicotine over a period of 16 or 24 hours (Di
Matteo et al., 2007). NRT increases the long-term rates
of smoking cessation and relieves craving for nicotine
and withdrawal syndrome (Rigotti, 2002).
17 Specific Non-Nicotine Treat-
ment
The eradicative approach involves the use of non-
nicotine compounds. Varenicline, a partial nicotine ag-
onist selectively binds to α4β2 nAChRs (Galanti, 2008).
As a partial agonist it partially stimulates receptor-
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mediated activity leading to the release of DA and
the consequent reduction of cravings and nicotine with-
drawal symptoms. Furthermore, it competes with nico-
tine for the nAChR binding site leading to a decrease in
its reinforcing effects (Coe et al., 2005).
Varenicline is considered the best smoking cessation
aid to date for long-term abstinence in the general popu-
lation, with comparison to bupropion (Hurt et al., 2009;
West el at., 2008) and NRT preparations (Aubin et al.,
2008). Several randomised control trials (RCTs) showed
that varenicline seems to be more efficient than bupro-
pion. For example, 2 studies (Gonzales et al., 2006;
Jorenby et al., 2006) showed that after a 12-week treat-
ment regime, the drug lead to a 44% abstinence rate,
versus 30% for bupropion SR and 18% for placebo.
The administration of bupropion, a phenylaminoketone
atypical antidepressant, was the first approved drug and
is now considered with other first-line pharmacological
treatments for nicotine addiction (Sutherland, 2002).
The action of bupropion seems to be multifactorial, in-
cluding (Hurt et al., 2009) inhibition of norepinephrine
(NA) and DA reuptake (Ascher et al., 1995), nAChR
antagonism (Slemmer et al., 2000). Sustained-release
bupropion (bupropion SR) has been shown to be more
effective and exhibits a significant dose-response effect
(Hurt et al., 1997). Additionally, bupropion SR together
with transdermal NRT lead to significantly higher long-
term rate of abstinence from smoking (Fiore et al., 2008;
Jorenby et al., 1999), since presumably NRT allevi-
ates nicotine withdrawal symptoms and antagonists re-
duce the rewarding effects of smoking (Di Matteo et al.,
2007).
18 Non-Specific Treatment
Other non-specific therapies, such as antidepressants,
are also used which inhibit NA and 5-HT reuptake (Di
Matteo et al., 2007). Smoking cessation has been shown
to increase depressive symptoms in many individuals
such that antidepressants are widely used to prevent
such manifestations (Busch et al., 2011). It is also im-
portant to note that nicotine, since it increases central
5-HT levels (Seth et al, 2002), can be a form of self-
medication for an underlying depression which might
then be unmasked upon smoking cessation (Borelli et
al., 1996).
19 Promising Treatment under
Trial
Electronic nicotine delivery systems (ENDS) are
cigarette-shaped electronic devices consisting of a
battery-powered heating element to vaporize a solution
containing nicotine and thence inhaled as a mist (Choi
and Forster, 2013). Both nicotine and smoking-related
cues appear to control cigarette craving and withdrawal
symptoms, therefore ENDS may be an effective smok-
ing cessation device (Caponnetto, 2012). Current ENDS
trials are evaluating smoking reduction and abstinence
effects, product preferences, and adverse effects of mar-
keted devices (Polosa, 2011).
Mecamylamine, a non-competitive nicotinic receptor
antagonist, has been evaluated for more than a decade
(Kirshenbaum et al., 2011; Lundahl et al., 2000). Its
non-competitive nature permits nicotine to bind, but
not to impose its receptor-mediated effects. This leads
to attenuation and eventually extinction of the condi-
tioned addictive behaviour of nicotine, since tobacco
consumption would not offer the same degree of mo-
tivation and reward. Such phenomenon is in fact shown
by a compensatory increase in smoking to make up for
the decreased nicotine-induced hedonia (Kirshenbaum
et al., 2011).
A Cochrane systematic review showed that opioid an-
tagonists, mainly naloxone, buprenorphine and naltrex-
one, have the potential to attenuate the rewarding ef-
fects of tobacco smoking since the central endogenous
circuitry has a role in reinforcing the smoking stimulus
(David et al., 2009).
Immunotherapy, also referred to as nicotine vaccina-
tion, could also be a promising solution in the near fu-
ture for the sphere of smoking cessation by injecting a
nicotine-like hapten, conjugated with a strong immuno-
gen, with the consequent production of nicotine anti-
bodies (Orson et al., 2008). Anti-nicotine antibodies
would then sequestrate intravascular nicotine after to-
bacco smoking or ingestion (Cornuz et al., 2008). On-
going phase III trials are expected to give rise to the
first nicotine vaccines in the coming years (Aubin et al.,
2011; Raupach et al., 2012).
20 Conclusion
The levels of consumption of tobacco are declining in
developed countries but increasing in developing ones
(Rigotti, 2002). Despite this fact, it is still the major
preventable cause of death and quit rates remain low
despite the availability of contemporary pharmacologi-
cal treatments aimed at the cessation of tobacco con-
sumption (Haas et al., 2004). Research has definitely
provided much more knowledge on the neurophysiology
of nicotine addiction on the human species. Despite the
fact that promising results have been obtained, one also
has to take into account the need for further obstacles
in both neuroadaptive mechanisms and treatment to be
surmounted. Some data is also obtained from exper-
iments on animal models or in vitro settings and not
from human trials. In addition, more research is needed
amongst youths, who are ultimately the most vulner-
able age group to addictive behaviour (PHS Guideline
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Update Panel, 2008; WHO, 2008).
More circumspect research coupled with non-
pharmacological approaches, public health awareness
and ethico-legal measures are sure to offer better out-
comes in the struggle against nicotine addiction and con-
comitant health hazards.
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Appendix 1
Criteria for Substance Dependence in
ICD-10
Three or more of the following must have been expe-
rienced or exhibited together at some time during the
previous year
1. a strong desire or sense of compulsion to take the
substance;
2. difficulties in controlling substance-taking be-
haviour in terms of its onset, termination, or levels
of use;
3. a physiological withdrawal state when substance
use has ceased or been reduced, as evidenced by:
the characteristic withdrawal syndrome for the sub-
stance; or use of the same (or a closely related)
substance with the intention of relieving or avoid-
ing withdrawal symptoms;
4. evidence of tolerance, such that increased doses of
the psychoactive substance are required in order to
achieve effects originally produced by lower doses;
5. progressive neglect of alternative pleasures or in-
terests because of psychoactive substance use, in-
creased amount of time necessary to obtain or take
the substance or to recover from its effects;
6. persisting with substance use despite clear evidence
of overtly harmful consequences, such as harm
to the liver through excessive drinking, depressive
mood states consequent to heavy substance use, or
drug-related impairment of cognitive functioning.
Efforts should be made to determine that the user
was actually, or could be expected to be, aware of
the nature and extent of the harm.
Source: World Health Organisation (1992). The ICD-
10 classification of mental and behavioural disorders:
clinical description and diagnostic guidelines. Geneva:
World Health Organisation. ISBN: 9241544228
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